Stock·NASDAQ·Healthcare
GE HealthCare Technologies Inc. (GEHC)
- Market cap
- $34.62B
- P/E
- 16.15
- Dividend yield
- 0.19%
- Street target
- $84.00median of 22 analysts
- 52-week range
- $58.75 $89.77
GEHC stock forecast today
Where GEHC stands today, and what CleaRank Financial AI makes of it.
GEHC at a glance
GE HealthCare Technologies Inc. (GEHC): Strong Buy, 82/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($68.45 and $69.82).
- Insiders Insiders bought $6.4M and made no open-market sales over the last 18 months.
- Valuation P/E of 16.2 against 31.9 for the Healthcare sector: a discount to peers (-49%).
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates GE HealthCare Technologies Inc. (GEHC) Strong Buy, with a model score of 82/100.
The trend lifts the score most: the price is 9.67% above its 200-day average and 11.86% above its 50-day average. The 50-day average stands at $68.45 and the 200-day at $69.82. Over the past year the price rose 2.09%.
Only on CleaRank
Figures we compute ourselves from GEHC's own price, earnings and insider-filing history. Tap one to see it in context.
GEHC stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $76.57 is 11.9% above the 50-day simple moving average of $68.45.Price above its 200-day average ›
The price is 9.7% above the 200-day simple moving average of $69.82.50-day average below the 200-day ›
The 50-day average ($68.45) is 2.0% below the 200-day average ($69.82), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 57% of its 52-week range, between $58.75 and $89.77.
GEHC share price
Pick a period: each tab shows how far GEHC has moved over it, to the last close.
Today's trading
Where GEHC sits inside today's range and its 52-week range.
GEHC fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 16.15 is 49.4% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 1.60 is 53.0% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $2.2B on revenue of $21.6B, a net margin of 10.0%.Pays a dividend ›
The trailing dividend yield is 0.19%, or $0.145 a share a year.
Key statistics
The headline figures for GEHC.
As of October 30, 2026, GEHC trades at $76.57, with a market value of $34.62B, a P/E ratio of 16.15 and a dividend yield of 0.19%.
What the numbers say
CleaRank Financial AI's reading of GEHC's valuation, growth and risks.
GE HealthCare Technologies Inc. (GEHC) screens as a discount to peers on earnings. Its P/E of 16.15 is 49.4% below the Healthcare sector median P/E of 31.9. On sales, its P/S of 1.60 is 52.9% below the sector median P/S of 3.4. The company's market capitalisation stands at $34.6B.
GEHC turns sales into profit at a net margin of 9.95% and an operating margin of 15.33%, alongside a return on equity of 20.01%, above the sector median of 7.3%. Debt-to-equity of 0.88 and a trailing dividend yield of 0.19% ($0.15 a share a year) round out the fundamentals.
GE HealthCare Technologies Inc. (GEHC) came in ahead of forecasts in its October 28, 2026 report, with EPS of $1.34 against the $1.20 analysts had penciled in, a beat of 11.67%. The shares followed through, rising 0.79% in the next session.
GEHC has beaten the EPS estimate in all 2 of its recent reports, though the stock still fell in the first session after 1 of those 2 beats. Analysts' average EPS estimate for this fiscal year is $4.92, which would be growth of 7.3%, and $5.41 for next year (growth of 9.9%).
On a typical day the price of GEHC shifts by 1.85%, the 30-day standard deviation of its daily returns with a beta of 0.85 against the S&P 500.
GEHC against the Healthcare sector
How GEHC compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: GEHC trades at a notable discount to sector peers (-49%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 20, 2025, GEHC has gained 6.6% against a gain of 37.3% for XLV.
Performance against XLV
GEHC and the Healthcare sector fund over the same days.
Revenue and earnings
How much GEHC sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); GEHC reported again on October 28, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 4.8% in FY2025 to $20.6B, from $19.7B a year earlier.
Profit margin: The net margin was 10.4% in FY2025, unchanged from the year before.
Profitable: GEHC earned $2.2B in FY2025.
Earnings reality check
Did GEHC beat what analysts expected, and how did the stock react?
Earnings record: GEHC beat the analyst estimate in 2 of the last 2 quarters.
Market reaction: The stock fell in the first session after 1 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 28, 2026after close | $1.20 | $1.34 | +11.67% | +0.79% | - |
| Feb 4, 2026after close | $1.40 | $1.44 | +2.86% | -0.39% | -4.15% |
As of October 30, 2026, GEHC has beaten the analyst EPS estimate in 2 of its last 2 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on October 28, 2026, came in 11.67% above the estimate and the stock moved +0.79% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
GEHC AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI overbought or oversold ›
The 14-day RSI is 74.1, in overbought territory.RSI above 50 ›
An RSI of 74.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of GEHC
The score, the reasoning behind it, and what could move the price next.
Both moving averages sit under the price, which is the shape of an uptrend for GE HealthCare Technologies Inc. (GEHC): the price of $76.57 is 11.86% above the 50-day average ($68.45) and 9.67% above the 200-day average ($69.82). The 50-day average runs 1.96% below the 200-day average, so the longer-run structure has not turned up yet, even with the price back above the shorter average. The 52-week range runs from $58.75 to $89.77, and today's price is 57% of the way up it.
Momentum is strong right now. The 14-day RSI sits at 74.1, which is overbought territory, and the MACD line is positive. Returns point the same way across the longer windows: the price is up 12.57% over the past three months, 25.46% over the past six months and 2.09% over the past year.
Earnings beat ›
The October 28, 2026 report beat the EPS estimate by 11.67%, and the share price rose 0.79% in the first session after it.
Source: Earnings report, October 28, 2026New analyst coverage ›
Barclays started coverage at Overweight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026New analyst coverage ›
Needham started coverage at Buy on September 22, 2026.
Source: Analyst action, Needham, September 22, 2026
- Two levels matter most here. The first is the 52-week high at $89.77, which sits above the price. The second is the 20-day EMA at $70.86, which sits below it.
- The 14-day RSI reads 74.1, which is in the overbought zone, while the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- GEHC beat estimates in 2 of the last 2 reports. After the October 28, 2026 report, the share price rose 0.79% in the first session.
GEHC is trading above its 50-day and 200-day moving averages ($68.45 and $69.82), and that is why the trend reads up. A drop through the 200-day would be the first sign of weakness. The closest level beneath the price is the 20-day EMA, at $70.86.
GE HealthCare Technologies Inc. (GEHC) has the 52-week high of $89.77 as its next level overhead. The RSI is in overbought territory, so a pause in the rally would not break the trend on its own. A slide back out of the bullish zone would be the clearer sign that momentum is fading.
Technical indicators
Momentum and trend for GEHC, from its daily closes.
As of October 30, 2026, with GEHC at $76.57, its 14-day RSI is 74.1 (overbought territory), its 50-day simple moving average is $68.45 and its 200-day is $69.82.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What GEHC moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, GEHC's 1-year correlation of daily returns is +0.49 with S&P 500 (SPY), +0.37 with Nasdaq 100 (QQQ), +0.06 with Bitcoin (BTC) and +0.06 with gold (XAU).
GEHC price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
16 of 22 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $84.00 is 9.7% above the price.No more buy ratings than three months ago ›
16 of 22 rate it a buy now, against 14 of 19 three months ago.
GEHC Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | BTIG | Maintains | Buy |
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Oct 5, 2026 | Citigroup | Maintains | Neutral |
| Oct 5, 2026 | Needham | Reiterates | Buy |
| Sep 22, 2026 | Needham | Initiates | Buy |
| Sep 17, 2026 | BTIG | Reiterates | Buy |
As of October 30, 2026, 22 Wall Street analysts cover GEHC: 16 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $70.00 to $96.00. The median GEHC price target is $84.00, 9.7% above the price of $76.57.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
GEHC trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
GEHC trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from GEHC's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much GEHC tends to move, against the market and on its own.
GEHC price history and drawdowns
GEHC's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 1.85% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 35.3%, from February 2025 to April 2025; the price is still 17.8% below that peak.Most 1-year holds did not end higher ›
37% of 1-year holding periods in the last 3 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in July 2023 is now worth $9,945, against $17,262 in the S&P 500 (SPY).
GEHC Drawdowns & Recovery
As of October 30, 2026, GEHC's worst peak-to-trough fall over the period since July 2023 with dividends reinvested was -35.3% (February 2025 to April 2025); it is still 17.8% below that peak, and 37% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into GEHC in July 2023 is worth now, against the same amount in the S&P 500.
Against the market: GEHC trailed the S&P 500 over this period: $9,945.43 against $17,262.
A $10,000 investment in GEHC in July 2023 would be worth about $9,945 today with dividends reinvested, compared with about $17,262 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to GEHC, and which have not.
Strongest month, February: an average of +9.65%, up in 2 of 3 years.
Weakest month, March: an average of -8.89%, up in 0 of 3 years.
This month, October: has averaged -3.47%, up in 1 of 3 years. Past seasonality does not repeat on schedule.
Over the last 4 years, GEHC's strongest calendar month has been February (average +9.65%, up in 2 of 3 years) and its weakest March (average -8.89%, up in 0 of 3 years).
Average return for each calendar month over the last 4 years, from weekly closing prices with dividends included.
GEHC stock price prediction 2029
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in GEHC, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 3-year Monte Carlo simulation, based on 3.3 years of price history, projects that a $10,000 investment in GEHC today could grow to about $11,414 by 2029 in the base case, with a 90th-percentile outcome near $23,807 and a 10th-percentile outcome around $5,472. The simulation models price only; at today's 0.19% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
GEHC Stock Price Prediction 2029: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $87.40 for GEHC by 2029 in the base case, from $76.57 today (1.1x over 3 years). The 10th-percentile path ends near $41.90. These are outcomes of a Monte Carlo simulation run on GEHC's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $52.34 | $80.02 | $122 | |
| 2028 | $45.88 | $83.63 | $152 | |
| 2029 | $41.90 | $87.40 | $182 |
Method: a lognormal simulation of GEHC's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
GEHC insider trading
What the people running the company have bought and sold.
GEHC insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider buying: Insiders bought $6.4M on the open market.
As of October 30, 2026, GEHC insiders reported no open-market sales and 8 open-market purchases worth $6.4M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | William K. Grogan
Chief Financial Officer
|
Grant | 75.1K | - |
| May 22, 2026 | Kevin A Lobo
Director
|
Buy | 10.0K | $641.8K |
| May 12, 2026 | Rodney F Hochman
Director
|
Buy | 1.6K | $100.4K |
| May 8, 2026 | Watkin Phoebe L Yang
Director
|
Buy | 1.0K | $63.0K |
| May 7, 2026 | Henry Lawrence Culp Jr.
Director
|
Grant | 7.7K | - |
| May 7, 2026 | Rodney F Hochman
Director
|
Grant | 6.3K | - |
| May 7, 2026 | Catherine Anne Lesjak
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Kevin A Lobo
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Anne T Madden
Director
|
Grant | 5.9K | - |
| May 7, 2026 | William J Stromberg
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Watkin Phoebe L Yang
Director
|
Grant | 3.6K | - |
| May 6, 2026 | Henry Lawrence Culp Jr.
Director
|
Buy | 80.8K | $5.0M |
| May 6, 2026 | William J Stromberg
Director
|
Buy | 1.0K | $61.7K |
| May 1, 2026 | James Saccaro
Chief Financial Officer
|
Buy | 3.3K | $200.6K |
| Apr 30, 2026 | Peter J Arduini
Chief Executive Officer
|
Buy | 4.2K | $249.8K |
| Apr 30, 2026 | Frank R Jimenez
General Counsel
|
Buy | 1.8K | $105.8K |
| Mar 13, 2026 | Kevin A Lobo
Director
|
Grant | 777 | - |
| Mar 2, 2026 | Peter J Arduini
Chief Executive Officer
|
Grant | 49.1K | - |
| Mar 2, 2026 | Jeannette Bankes
Officer
|
Grant | 6.9K | - |
| Mar 2, 2026 | Adam Y Holton
Officer
|
Grant | 5.5K | - |
| Mar 2, 2026 | Frank R Jimenez
General Counsel
|
Grant | 10.9K | - |
| Mar 2, 2026 | Taha Kass-Hout
Chief Technology Officer
|
Grant | 13.3K | - |
| Mar 2, 2026 | George A. Newcomb
Officer
|
Grant | 1.3K | - |
| Mar 2, 2026 | Kevin Michael O'Neill
Officer
|
Grant | 6.5K | - |
| Mar 2, 2026 | Philip Rackliffe
Officer
|
Grant | 9.4K | - |
| Mar 2, 2026 | Roland Rott
Officer
|
Grant | 8.6K | - |
| Mar 2, 2026 | James Saccaro
Chief Financial Officer
|
Grant | 12.5K | - |
| Feb 12, 2026 | Peter J Arduini
Chief Executive Officer
|
Grant | 74.9K | - |
| Feb 12, 2026 | Frank R Jimenez
General Counsel
|
Grant | 22.1K | - |
| Feb 12, 2026 | Taha Kass-Hout
Chief Technology Officer
|
Grant | 23.3K | - |
| Feb 12, 2026 | George A. Newcomb
Officer
|
Grant | 2.5K | - |
| Feb 12, 2026 | Kevin Michael O'Neill
Officer
|
Grant | 6.9K | - |
| Feb 12, 2026 | Philip Rackliffe
Officer
|
Grant | 3.2K | - |
| Feb 12, 2026 | Roland Rott
Officer
|
Grant | 7.9K | - |
| Feb 12, 2026 | James Saccaro
Chief Financial Officer
|
Grant | 22.6K | - |
| Sep 11, 2025 | Roland Rott
Officer
|
Option | 5.3K | $298.6K |
| Aug 15, 2025 | Kenneth Robert Stacherski
Officer
|
Grant | 10.2K | - |
| May 28, 2025 | Henry Lawrence Culp Jr.
Director
|
Grant | 6.7K | - |
| May 28, 2025 | Rodney F Hochman
Director
|
Grant | 4.8K | - |
| May 28, 2025 | Lloyd Howell Jr
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Risa J Lavizzo-Mourey
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Catherine Anne Lesjak
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Anne T Madden
Director
|
Grant | 4.8K | - |
| May 28, 2025 | Tomislav Mihaljevic
Director
|
Grant | 3.1K | - |
| May 28, 2025 | William J Stromberg
Director
|
Grant | 5.1K | - |
| May 28, 2025 | Watkin Phoebe L Yang
Director
|
Grant | 3.1K | - |
| May 15, 2025 | Jeannette Bankes
Officer
|
Grant | 37.0K | - |
Source: TwelveData, from SEC Form 4 filings
GEHC stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.